A Report by the American Academy of Ophthalmology

Ophthalmic Technology Assessment Committee Glaucoma Panel: Don S. Minckler, MD, MS; Brian A. Francis, MD; Elizabeth A. Hodapp, MD; Henry D. Jampel, MD, MHS; Shan C. Lin, MD; John R. Samples, MD; Scott D. Smith, MD, MPH; Kuldev Singh, MD, MPH

• Evidence-based summary of aqueous shunts including
  - Ahmed
  - Baerveldt
  - Krupin
  - Molteno
• Level I evidence that shunts have benefits (IOP control, duration of benefit) comparable with trabeculectomy
• Clinical failure of devices is approximately 10% per year
• Level I evidence of no advantage to using adjunctive antifibrotic agents or systemic corticosteroids